Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,827 across all filing types
Latest filing 2021-02-23 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
哈药集团股份有限公司九届四次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board resolution announcement from 哈药集团股份有限公司 (Harbin Pharmaceutical Group Co., Ltd.) regarding the approval of a 2021 stock option and restricted stock incentive plan and related management measures. It details the board meeting date, voting results, and the authorization of the board to handle matters related to the incentive plan. It also mentions that the proposals will be submitted to the shareholders' meeting for approval. The document is not a full report but an announcement of board decisions and upcoming shareholder meeting. It does not contain financial statements or detailed financial data. Therefore, it fits best under Board/Management Information (MANG) as it relates to board resolutions and management decisions.
2021-02-23 Chinese
哈药集团股份有限公司监事会关于公司2021年股票期权与限制性股票激励计划相关事项的核查意见
Regulatory Filings Classification · 95% confidence The document is a supervisory board's verification opinion on the company's 2021 stock option and restricted stock incentive plan. It discusses compliance with relevant laws and regulations, eligibility of incentive recipients, and the approval process. It does not contain financial statements or detailed financial data, nor is it an announcement of voting results or a proxy solicitation. It is a regulatory compliance and internal governance-related document concerning a stock incentive plan. Given the content and length (1343 characters), it is not a full report but a regulatory filing related to governance and compliance matters. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2021-02-23 Chinese
哈药集团股份有限公司2021年股票期权与限制性股票激励计划首次授予部分激励对象名单
Regulatory Filings Classification · 95% confidence The document is titled as a list of recipients for a 2021 stock option and restricted stock incentive plan by 哈药集团股份有限公司 (Harbin Pharmaceutical Group Co., Ltd.). It details the allocation of stock options and restricted stocks to various executives and core employees, including their positions and the number of shares/options granted. The document includes tables with specific allocation numbers and percentages relative to total stock and stock options. There is no indication of financial statements, audit opinions, or comprehensive financial performance data. The document is not a report like an Annual Report or Interim Report but rather an announcement or disclosure related to stock incentive plans. This type of document fits best under the category of Regulatory Filings (RNS) as it is a regulatory disclosure about stock incentive allocations and does not fit other more specific categories such as Director's Dealing or Share Issue/Capital Change, since it is about incentive plan allocations rather than actual share transactions or capital changes. The document length is under 5,000 characters, and it is a direct disclosure rather than a report publication announcement. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2021-02-23 Chinese
哈药集团股份有限公司独立董事关于公司九届四次董事会相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors of 哈药集团股份有限公司 regarding the company's 2021 stock option and restricted stock incentive plan and its implementation assessment management measures. It discusses compliance with relevant laws and regulations, qualifications of incentive recipients, and the rationale and benefits of the incentive plan. The document is a formal opinion related to board matters, specifically about a stock incentive plan proposal to be submitted to the shareholders' meeting. It does not contain financial statements or quarterly/yearly financial results, nor is it a transcript, audit report, or regulatory filing. It is a board-related document expressing independent directors' opinions on board resolutions. Therefore, it fits best under Board/Management Information (MANG). The document length is short (1952 characters), and it is not merely an announcement or certification but a substantive opinion on board matters.
2021-02-23 Chinese
哈药集团股份有限公司关于分公司对外出售闲置房产的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the sale of idle property by a subsidiary of the company. It details the transaction parties, property description, contract terms, and the expected financial impact. The document is relatively short (1480 characters) and serves as a formal disclosure of a specific transaction rather than a comprehensive financial report or management discussion. It does not contain financial statements or detailed financial analysis. This fits the category of a Capital/Financing Update (CAP), as it relates to asset disposal and capital management activities.
2021-02-08 Chinese
哈药集团股份有限公司九届三次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board resolution announcement regarding the approval of a bank loan application by the company's board of directors. It details the board meeting date, attendance, voting results, and authorization for management to proceed with loan arrangements. There is no financial report, earnings data, or regulatory certification. The content fits the category of Board/Management Information (MANG) as it announces a board decision on financing matters, but it is not a direct Capital/Financing Update (CAP) since it is a board resolution announcement rather than a financing event update. Given the focus on board decision-making, MANG is the most appropriate classification.
2021-02-05 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.